Table 5.
siRNA employment in hepatocellular carcinoma.
| Target mRNA | Delivery System | Tumor Model | Ref. |
|---|---|---|---|
| FMRP * | Carbon dots conjugated with the aptamer AS1411 | HepG2 | Zhao et al. [75] |
| Survivin and VEGF * | Galactose-modified trimethyl chitosan-cysteine | Xenograft mouse model of HCC | Han et al. [76] |
| eEF1A1, eEF1A2 *, E2F1 | PDPG polymer bound to galactose | HuH7; Xenograft mouse model of HCC | Perrone et al. [77] |
| Pin1 | GalNac-siRNA embedded into a gel | Orthotopic mouse model | Zhao et al. [78] |
| RRM2 * | liposome-polycation-DNA complexes linked to anti-EGFR * Fab’ | Orthotopic mouse model | Gao et al. [79] |
| TERT * | PEGylated liposomes conjugated with antibodies against TfR * and HIR * | Xenograft mouse model of HCC | Hu et al. [80] |
| VEGF * | Polymer containing urocanic acid-modified galactosylated trimethyl chitosan | QGY-7703; mouse xenograft subcutaneous model | Han et al. [81] |
| Survivin | PEG/PEI conjugated with RGD * | Subcutaneous mouse model | Wu et al. [82] |
* FMRP: Fragile X mental retardation protein; VEGF: Vascular Endothelial Growth Factor; eEF1A1/2: eukaryotic elongation factor 1A1/2; RRM2: ribonucleotide reductase M2; EGFR: Epidermal growth factor receptor; TERT: telomerase reverse transcriptase; TfR: transferrin receptor; HIR: human insulin receptor; RGD: tripeptide arginine glycine aspartic acid.